NCT06162559View on ClinicalTrials.gov

Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

May 31, 2036

Conditions
Breast Cancer
Interventions
DRUG

Tucatinib

Tucatinib 300mg is taken orally twice daily

DRUG

Trastuzumab

Trastuzumab 6mg/kg is administered intravenously on day 1 (loading dose 8mg/kg) or subcutaneously 600mg on day 1 of each cycle

DRUG

Pertuzumab

Pertuzumab 420mg is administered intravenously on day 1 (loading dose 840mg) or subcutaneously 600mg/kg (loading dose 1200mg) on day 1 of each cycle

Trial Locations (1)

1066CX

RECRUITING

Netherlands Cancer Institute, Amsterdam

All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER